Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O) (MOHCCN-O)

June 9, 2026 updated by: University Health Network, Toronto

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

Study Overview

Status

Recruiting

Conditions

Detailed Description

The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.

Study Type

Observational

Enrollment (Estimated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: PM2C Central Office
Phone Number: 3486 416-946-4501
Email: MOHCCN@uhn.ca

Study Locations

Canada
- Ontario
  - Kingston, Ontario, Canada, K7L 2V7
    - Recruiting
    - Kingston Health Sciences Centre
    - Contact:
      
      Heather Grant
      
      Phone Number: 613-548-2517
      
      Email: granth@queensu.ca
    - Principal Investigator:
      
      Amber Simpson, PhD
  - Ottawa, Ontario, Canada, K1Y 4E9
    - Not yet recruiting
    - Ottawa Health Research Institute
    - Principal Investigator:
      
      Rebecca Auer, MD
    - Contact:
      
      Leonard Angka, PhD
      
      Phone Number: 71111 613-737-8899
      
      Email: langka@ohri.ca
  - Toronto, Ontario, Canada, M5G2M9
    - Recruiting
    - Princess Margaret Cancer Centre
    - Principal Investigator:
      
      Lillian Siu, MD
    - Contact:
      
      PM2C Central Office
      
      Phone Number: 3486 416-946-4501
      
      Email: MOHCCN@uhn.ca

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Sampling Method

Non-Probability Sample

Study Population

Any cancer patient

Description

Inclusion Criteria:

Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy
All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:
1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)
2. Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization
Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.
Participating patients must agree to share their anonymized clinical and genomic data

Exclusion Criteria:

None.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort
MOHCCN-O Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.

Group / Cohort

MOHCCN-O

Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data Time Frame: 5 years	Consolidate and annotate data from patients included in a pan-Canadian cohort	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions Time Frame: 5 years	Health technology assessment tools will be used to evaluate the real-world value of precision medicine	5 years
Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine Time Frame: 5 years	Health technology assessment tools will be used to evaluate the real-world value of precision medicine	5 years
Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases Time Frame: 5 years	Improve the cancer research paradigm by bringing teams or researchers together and leverage valuable information genomic and clinical data from Canadian cancer cases.	5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Health Network, Toronto

Collaborators

Ottawa Hospital Research Institute

London Health Sciences Centre

Princess Margaret Hospital, Canada

Queen's University, Kingston, Ontario

University of Windsor

Windsor Regional Hospital

Ontario Institute for Cancer Research

Terry Fox Research Institute

Kingston Health Sciences Centre

London Health Sciences Centre Research Institute

Investigators

Principal Investigator: Lillian Siu, MD, University Health Network, Toronto

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 23, 2022

Primary Completion (Estimated)

April 1, 2030

Study Completion (Estimated)

October 1, 2030

Study Registration Dates

First Submitted

May 30, 2022

First Submitted That Met QC Criteria